Skip to main content
Top
Published in: Annals of Nuclear Medicine 8/2012

01-10-2012 | Original article

Comparison of diagnostic ability between 99mTc-MDP bone scan and 18F-FDG PET/CT for bone metastasis in patients with small cell lung cancer

Authors: Jeong Won Lee, Sang Mi Lee, Ho Sung Lee, Yong Hoon Kim, Won Kyoung Bae

Published in: Annals of Nuclear Medicine | Issue 8/2012

Login to get access

Abstract

Objective

The aim of this study was to compare the diagnostic ability of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) with that of 99mTc-methylene diphosphonate (99mTc-MDP) bone scan for bone metastasis in staging patients with small cell lung cancer (SCLC).

Methods

Ninety-five patients with SCLC who underwent both 18F-FDG PET/CT and 99mTc-MDP bone scan for initial staging work-up were retrospectively enrolled. All 18F-FDG PET/CT and bone scan images were visually assessed. Bone metastasis was confirmed by histopathological results and all available clinical information.

Results

Of 95 patients with SCLC, metastatic bone lesions were found in 30 patients, and 84 metastatic lesions were evaluated on a lesion-basis analysis. The sensitivity of 18F-FDG PET/CT was 100 % on a per-patient basis and 87 % on a per-lesion basis, and there was no false-positive lesion on PET/CT images. In contrast, the sensitivity of the bone scan was 37 % on a per-patient basis and 29 % on a per-lesion basis. The bone scan showed 11 false-positive lesions. The bone scan detected two metastatic lesions that were not detected by PET/CT, which were outside the region scanned by PET/CT. On follow-up bone scan, 21 lesions that were not detected by the initial bone scan but were detected by PET/CT were newly detected.

Conclusions

In patients with SCLC, 18F-FDG PET/CT showed higher detection rate of bone metastasis than 99mTc-MDP bone scan. Thus, 18F-FDG PET/CT can replace bone scan in staging patients with SCLC.
Literature
1.
go back to reference Felip E, Pavlidis N, Stahel RA. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC). Ann Oncol. 2005;16(Suppl 1):i30–1.PubMedCrossRef Felip E, Pavlidis N, Stahel RA. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC). Ann Oncol. 2005;16(Suppl 1):i30–1.PubMedCrossRef
3.
go back to reference Argiris A, Murren JR. Staging and clinical prognostic factors for small-cell lung cancer. Cancer J. 2001;7:437–47.PubMed Argiris A, Murren JR. Staging and clinical prognostic factors for small-cell lung cancer. Cancer J. 2001;7:437–47.PubMed
4.
go back to reference Elliott JA, Osterlind K, Hirsch FR, Hansen HH. Metastatic patterns in small-cell lung cancer: correlation of autopsy findings with clinical parameters in 537 patients. J Clin Oncol. 1987;5:246–54.PubMed Elliott JA, Osterlind K, Hirsch FR, Hansen HH. Metastatic patterns in small-cell lung cancer: correlation of autopsy findings with clinical parameters in 537 patients. J Clin Oncol. 1987;5:246–54.PubMed
5.
go back to reference Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol. 2004;22:3248–54.PubMedCrossRef Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol. 2004;22:3248–54.PubMedCrossRef
6.
go back to reference Arslan N, Tuncel M, Kuzhan O, Alagoz E, Budakoglu B, Ozet A, et al. Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-d-glucose with positron emission tomography in patients with small cell lung cancer. Ann Nucl Med. 2011;25:406–13.PubMedCrossRef Arslan N, Tuncel M, Kuzhan O, Alagoz E, Budakoglu B, Ozet A, et al. Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-d-glucose with positron emission tomography in patients with small cell lung cancer. Ann Nucl Med. 2011;25:406–13.PubMedCrossRef
7.
go back to reference Chin R Jr, McCain TW, Miller AA, Dunagan DP, Acostamadiedo J, Douglas Case L, et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer. 2002;37:1–6.PubMedCrossRef Chin R Jr, McCain TW, Miller AA, Dunagan DP, Acostamadiedo J, Douglas Case L, et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer. 2002;37:1–6.PubMedCrossRef
8.
go back to reference Brink I, Schumacher T, Mix M, Ruhland S, Stoelben E, Digel W, et al. Impact of [18F] FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2004;31:1614–20.PubMedCrossRef Brink I, Schumacher T, Mix M, Ruhland S, Stoelben E, Digel W, et al. Impact of [18F] FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2004;31:1614–20.PubMedCrossRef
9.
go back to reference Fischer BM, Mortensen J, Langer SW, Loft A, Berthelsen AK, Petersen BI, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol. 2007;18:338–45.PubMedCrossRef Fischer BM, Mortensen J, Langer SW, Loft A, Berthelsen AK, Petersen BI, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol. 2007;18:338–45.PubMedCrossRef
10.
go back to reference Vinjamuri M, Craig M, Campbell-Fontaine A, Almubarak M, Gupta N, Rogers JS. Can positron emission tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer. 2008;9:30–4.PubMedCrossRef Vinjamuri M, Craig M, Campbell-Fontaine A, Almubarak M, Gupta N, Rogers JS. Can positron emission tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer. 2008;9:30–4.PubMedCrossRef
11.
go back to reference Oh JR, Seo JH, Chong A, Min JJ, Song HC, Kim YC, et al. Whole-body metabolic tumour volume of (18)F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;. doi:10.1007/s00259-011-2059-7.PubMed Oh JR, Seo JH, Chong A, Min JJ, Song HC, Kim YC, et al. Whole-body metabolic tumour volume of (18)F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;. doi:10.​1007/​s00259-011-2059-7.PubMed
12.
go back to reference Shen YY, Shiau YC, Wang JJ, Ho ST, Kao CH. Whole-body 18F–2-deoxyglucose positron emission tomography in primary staging small cell lung cancer. Anticancer Res. 2002;22:1257–64.PubMed Shen YY, Shiau YC, Wang JJ, Ho ST, Kao CH. Whole-body 18F–2-deoxyglucose positron emission tomography in primary staging small cell lung cancer. Anticancer Res. 2002;22:1257–64.PubMed
13.
go back to reference Schumacher T, Brink I, Mix M, Reinhardt M, Herget G, Digel W, et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med. 2001;28:483–8.PubMedCrossRef Schumacher T, Brink I, Mix M, Reinhardt M, Herget G, Digel W, et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med. 2001;28:483–8.PubMedCrossRef
14.
go back to reference Kut V, Spies W, Spies S, Gooding W, Argiris A. Staging and monitoring of small cell lung cancer using [18F] fluoro-2-deoxy-d-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol. 2007;30:45–50.PubMedCrossRef Kut V, Spies W, Spies S, Gooding W, Argiris A. Staging and monitoring of small cell lung cancer using [18F] fluoro-2-deoxy-d-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol. 2007;30:45–50.PubMedCrossRef
15.
go back to reference Gontier E, Vaylet F, Bonardel G, Mantzarides M, Salles Y, Guigay J, et al. 18-FDG positon emission tomography and distal metastasis from lung cancer. Rev Pneumol Clin. 2005;61:248–57.PubMedCrossRef Gontier E, Vaylet F, Bonardel G, Mantzarides M, Salles Y, Guigay J, et al. 18-FDG positon emission tomography and distal metastasis from lung cancer. Rev Pneumol Clin. 2005;61:248–57.PubMedCrossRef
16.
go back to reference Bezwoda WR, Lewis D, Livini N. Bone marrow involvement in anaplastic small cell lung cancer. Diagnosis, hematologic features, and prognostic implications. Cancer. 1986;58:1762–5.PubMedCrossRef Bezwoda WR, Lewis D, Livini N. Bone marrow involvement in anaplastic small cell lung cancer. Diagnosis, hematologic features, and prognostic implications. Cancer. 1986;58:1762–5.PubMedCrossRef
17.
go back to reference Galasko CS. Mechanisms of bone destruction in the development of skeletal metastases. Nature. 1976;263:507–8.PubMedCrossRef Galasko CS. Mechanisms of bone destruction in the development of skeletal metastases. Nature. 1976;263:507–8.PubMedCrossRef
18.
go back to reference Imamura F, Kuriyama K, Seto T, Hasegawa Y, Nakayama T, Nakamura S, et al. Detection of bone marrow metastases of small cell lung cancer with magnetic resonance imaging: early diagnosis before destruction of osseous structure and implications for staging. Lung Cancer. 2000;27:189–97.PubMedCrossRef Imamura F, Kuriyama K, Seto T, Hasegawa Y, Nakayama T, Nakamura S, et al. Detection of bone marrow metastases of small cell lung cancer with magnetic resonance imaging: early diagnosis before destruction of osseous structure and implications for staging. Lung Cancer. 2000;27:189–97.PubMedCrossRef
19.
go back to reference Levenson RM Jr, Sauerbrunn BJ, Ihde DC, Bunn PA Jr, Cohen MH, Minna JD. Small cell lung cancer: radionuclide bone scans for assessment of tumor extent and response. Am J Roentgenol. 1981;137:31–5. Levenson RM Jr, Sauerbrunn BJ, Ihde DC, Bunn PA Jr, Cohen MH, Minna JD. Small cell lung cancer: radionuclide bone scans for assessment of tumor extent and response. Am J Roentgenol. 1981;137:31–5.
20.
go back to reference Levitan N, Byrne RE, Bromer RH, Faling LJ, Caslowitz P, Pattern DH, et al. The value of the bone scan and bone marrow biopsy staging small cell lung cancer. Cancer. 1985;56:652–4.PubMedCrossRef Levitan N, Byrne RE, Bromer RH, Faling LJ, Caslowitz P, Pattern DH, et al. The value of the bone scan and bone marrow biopsy staging small cell lung cancer. Cancer. 1985;56:652–4.PubMedCrossRef
21.
go back to reference Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005;32:1253–8.PubMedCrossRef Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005;32:1253–8.PubMedCrossRef
22.
go back to reference Kruger S, Buck AK, Mottaghy FM, Hasenkamp E, Pauls S, Schumann C, et al. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:1807–12.PubMedCrossRef Kruger S, Buck AK, Mottaghy FM, Hasenkamp E, Pauls S, Schumann C, et al. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:1807–12.PubMedCrossRef
23.
go back to reference Koolen BB, Vegt E, Rutgers EJ, Vogel WV, Stokkel MP, Hoefnagel CA, et al. FDG-avid sclerotic bone metastases in breast cancer patients: a PET/CT case series. Ann Nucl Med. 2012;26:86–91.PubMedCrossRef Koolen BB, Vegt E, Rutgers EJ, Vogel WV, Stokkel MP, Hoefnagel CA, et al. FDG-avid sclerotic bone metastases in breast cancer patients: a PET/CT case series. Ann Nucl Med. 2012;26:86–91.PubMedCrossRef
Metadata
Title
Comparison of diagnostic ability between 99mTc-MDP bone scan and 18F-FDG PET/CT for bone metastasis in patients with small cell lung cancer
Authors
Jeong Won Lee
Sang Mi Lee
Ho Sung Lee
Yong Hoon Kim
Won Kyoung Bae
Publication date
01-10-2012
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 8/2012
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-012-0622-3

Other articles of this Issue 8/2012

Annals of Nuclear Medicine 8/2012 Go to the issue